https://en.banglaoutlook.org/editors-pick/236108 Bangla Outlook English bn 2026-06-24T21:31:55+06:00 Whistleblower alleges Beximco-linked importer exploited regulatory loophole on children’s diarrhoea treatment Enterogermina Bangladesh, Enterogermina Oral Suspension, Enterogermina price Bangladesh, probiotic Bangladesh, children's probiotic, pediatric probiotic, diarrhea treatment Bangladesh, childhood diarrhea, Bacillus clausii, Bacillus clausii probiotic, probiotic supplement, digestive health supplement, pediatric healthcare Bangladesh, food supplement Bangladesh, imported food supplement, healthcare pricing Bangladesh, pharmaceutical pricing, medicine pricing controversy, healthcare market Bangladesh, drug regulation Bangladesh, supplement regulation Bangladesh, DGDA Bangladesh, Directorate General of Drug Administration, Drugs and Cosmetics Act 2023, pharmaceutical imports Bangladesh, imported healthcare products, pharmaceutical oversight, healthcare regulation, food supplement regulation, drug registration Bangladesh, pharmaceutical compliance, healthcare industry Bangladesh, medical products Bangladesh, pediatric nutrition products, gastrointestinal treatment, diarrhea management, child health Bangladesh, healthcare affordability, consumer health products, healthcare costs Bangladesh, pharmaceutical profits, profit margins pharmaceutical industry, medical product markup, healthcare business Bangladesh, pharmaceutical distribution, pharmaceutical marketing Bangladesh, healthcare economics, pharmaceutical pricing practices, import pricing, customs valuation, under-invoicing allegations, customs investigation, import documentation, customs scrutiny, import regulation Bangladesh, pharmaceutical imports investigation, regulatory compliance, import authorization, No Objection Certificate NOC, pharmaceutical licensing, healthcare transparency, consumer protection Bangladesh, healthcare accountability, pharmaceutical ethics, drug market Bangladesh, supplement market Bangladesh, probiotic market Bangladesh, pediatric supplement market, pharmaceutical competition, local pharmaceutical alternatives, domestic pharmaceutical industry, import substitution policy, healthcare policy Bangladesh, pharmaceutical sector Bangladesh, Beximco Pharmaceuticals, Beximco Pharma, Synovia Pharma, Synovia Pharma PLC, Beximco affiliated company, Beximco healthcare business, Beximco controversy, pharmaceutical allegations, whistleblower allegations, insider claims, corporate governance Bangladesh, healthcare industry investigation, pharmaceutical industry scrutiny, pharmaceutical imports from Italy, Italian healthcare products, imported probiotics, medical supplement pricing, healthcare consumers, patient affordability, pharmaceutical profit analysis, retail medicine prices, healthcare access Bangladesh, pharmaceutical regulation debate, healthcare market oversight, pricing transparency, pharmaceutical supply chain, customs intelligence, healthcare product approval, free sale certificate, certificate of analysis, manufacturing data, stability data, pharmaceutical documentation, healthcare compliance requirements, medical product imports, Bangladesh healthcare news, pharmaceutical sector news, healthcare watchdog issues, drug administration oversight, public health policy, child healthcare costs, healthcare affordability crisis, consumer rights in healthcare, market competition in healthcare, pharmaceutical market dynamics, healthcare business ethics, pricing controversy Bangladesh, import valuation dispute, healthcare journalism, investigative reporting Bangladesh, Zulkarnain Saer, Bangla Outlook investigation, pharmaceutical industry report, healthcare sector analysis, Bangladesh business news, regulatory oversight failures, health supplement controversy, pharmaceutical accountability, healthcare governance, medical consumer protection, pediatric medicine alternatives, healthcare industry transparency, healthcare procurement, pharmaceutical sales Bangladesh, medical supplement market analysis